摘要
基因重组人促红细胞生成素(rHuEPO)是治疗肾性贫血的主要药物,2012年改善全球肾脏病预后组织(KDI-GO)贫血治疗指南根据最新的研究结果对EPO在慢性肾脏病的应用规范提出了建议。本文将从血红蛋白目标值、EPO治疗的启动时机、给药方案、EPO的反应性等方面进行讨论,探寻更加合理的EPO应用策略。在纠正贫血的过程中,应兼顾EPO治疗的获益和风险。
Human erythropoietin has been the mainstay treatment of renal anemia. The 2012 guideline for treatment of ane mia, drafted by Kidney Disease ： Improving Global Outcomes （KDIGO） , issued the recommendations for clinical application of human erythropoietin in patients with chronic kidney disease based on the latest literature report. This review was de signed to delineate the target concentration of hemoglobin, initiation of erythropoietin therapy, protocols for administration and the efficacy, thus optimizing the use of erythropoietin. The merits and potential risks of erythropoietin should be carefully weighed in the treatment of anemia.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2012年第12期900-902,共3页
Chinese Journal of Practical Internal Medicine
关键词
促红细胞生成素
慢性肾脏病
贫血
EPO低反应性
erythropoietin
chronic kidney disease
anemia
erythropoietin hyporesponsiveness
